Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2014-03-18 Regulatory Filings
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed by Lipocine Inc. dated March 18, 2014. It announces the approval of the company's common stock for listing on the NASDAQ Capital Market and the expected commencement of trading under the symbol "LPCN". The document includes a press release as an exhibit and does not contain financial statements or detailed financial analysis. It is primarily an announcement of a corporate event related to capital markets listing, not a financial report or earnings release. The document is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or management report. It is a regulatory filing reporting a significant corporate event. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (7688 characters) and content support this classification with high confidence.
2014-03-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the approval of the company's common stock for listing on the NASDAQ Capital Market and the expected commencement of trading. There is no detailed financial data, management discussion, or audit information. The document is short (2425 characters) and includes a press release as an exhibit. This type of filing is an event-driven regulatory announcement rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2014-03-18 English
13G LPCN 2-14-2014
Major Shareholding Notification
2014-02-14 English
SC 13G/A
Major Shareholding Notification
2014-02-14 English
RULE 424(B)(3)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed by Lipocine Inc. dated February 10, 2014. It includes a prospectus supplement related to a registration statement and a current report on Form 8-K. The content includes a press release announcing the first patient dosed in a Phase 3 clinical trial and a company presentation attached as exhibits. The document is primarily an announcement of events and investor communications rather than a full financial report or detailed financial statements. It does not contain quarterly or annual financial results, audit opinions, or management discussion and analysis. The presence of a press release and presentation related to clinical trial progress and investor meetings aligns with a Capital/Financing Update or investor communication. However, since it is a Form 8-K filing with press releases and presentations attached, and it does not fit into other specific categories like earnings release or annual report, the best classification is Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not neatly fit into other categories.
2014-02-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a Regulation FD Disclosure about a presentation at a healthcare conference and a press release about a clinical trial milestone. It includes exhibits such as a press release and a company presentation. The document is short (2821 characters) and primarily serves to announce events and provide related materials rather than containing detailed financial data or full reports. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-02-10 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.